Pharmacotherapy prior to and in acute ischaemic stroke. the use of pharmacotherapy and drugs-associated outcomes in real-world practice - Findings from the Polish Hospital Stroke Registry;Farmakoterapia w okresie poprzedzającym wystąpienie udaru i w ostrym udarze niedokrwiennym. zastosowanie oraz wpływ leków na wyniki leczenia udaru niedokrwiennego mózgu w codziennej praktyce klinicznej - Wyniki Szpitalnego Rejestru Udarów Mózgu w Polsce

Neurologia i Neurochirurgia Polska

Volumn 47, Issue 6, 2013, Pages 509-516

  Niewada, Maciej ^a   Sarzyńska Długosz, Iwona Marta ^b   Skowrońska, Marta ^b   Kamiński, Bogumił ^c   Kobayashi, Adam ^a   Członkowska, Anna ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^c WARSAW SCHOOL OF ECONOMICS   (Poland)

Author keywords

Antihypertensives; Aspirin; Ischaemic stroke; Oral anticoagulants; Pharmacotherapy; Statins

Indexed keywords

EID: 84890021994     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.5114/ninp.2013.39067     Document Type: Article

References (29)

1. Rothwell P.M., Coull A.J., Giles M.F., et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363: 1925-1933.
2. O'Donnell M.J., Xavier D., Liu L., et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376: 112-123.
3. Wytyczne Grupy Ekspertów Narodowego Programu Profilaktyki i Leczenia Udaru Mózgu dotycza{ogonek}ce organizacji pododdzia łów udarowych. Neurol Neurochir Pol 2003; 37: 11-16.
4. Grupa Ekspertów Narodowego Programu Profilaktyki i Le-czenia Chorób Układu Sercowo-Naczyniowego POLKARD. Postêpowanie w udarze mózgu. Wytyczne Grupy Ekspertów Narodowego Programu Profilaktyki i Leczenia Chorób Układu Sercowo-Naczyniowego POLKARD. Neurol Neurochir Pol 2008; 42: S201-S288.
5. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.
6. Prepared on behalf of the Intercollegiate Stroke Working Party by Clinical Effectiveness and Evaluation Unit Royal College of Physicians of London. National Sentinel Stroke Audit Phase 1 (organisational audit) 2006 Phase 2 (clinical audit) 2006, kwiecieñ 2007; http://www.rcplondon.ac.uk/sites/default/files/org_and_clinical_2006_concise-stroke-audit-round-5_2007.pdf (accessed: 25.02.2013).
7. Appelros P., Jonsson F., Asplund K., et al. Trends in baseline pa-tient characteristics during the years 1995-2008: observations from Riks-Stroke, the Swedish Stroke Register. Cerebrovasc Dis 2010; 30: 114-119.
8. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349: 1569-1581.
9. CAST: randomised placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997; 349: 1641-1649.
10. Sandercock P.A., Counsell C., Gubitz G.J., et al. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2008: CD000029.
11. Nowacki P., Bajer-Czajkowska A., Masztalewicz M. Clinical characteristics of early and late recurrent ischaemic stroke. Neurol Neurochir Pol 2010; 44: 123-130.
12. Sposato L.A., Esnaola M.M., Zamora R., et al. Quality of ischae-mic stroke care in emerging countries: the Argentinian National Stroke Registry (ReNACer). Stroke 2008; 39: 3036-3041.
13. Barber A., Charleston A., Anderson N., et al. Changes in stroke care at Auckland Hospital between 1996 and 2001. N ZMed J 2004; 117: U797.
14. Glader E.L., Stegmayr B., Norrving B., et al. Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: a Swedish national perspective. J Int Med 2004; 255: 22-32.
15. Jorgensen H.S., Nakayama H., Reith J., et al. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 1997; 48: 891-895.
16. Lamassa M., Di Carlo A., Pracucci G., et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32: 392-398.
17. Deplanque D., Leys D., Parnetti L., et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004; 57: 798-806.
18. Sherman D.G., Albers G.W., Bladin C., et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 2007; 369: 1347-1355.
19. Sherman D.G. Prevention of venous thromboembolism, recurrent stroke, and other vascular events after acute ischaemic stroke: the role of low-molecular-weight heparin and antiplatelet therapy. J Stroke Cerebrovasc Dis 2006; 15: 250-259.
20. Sandercock P.A., Counsell C., Kamal A.K. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2008: CD000024.
21. Eriksson M., Stecksen A., Glader E.L., et al. Discarding he pa-rins as treatment for progressive stroke in Sweden 2001 to 2008. Stroke 2010; 41: 2552-2558.
22. Chamorro A., Horcajada J.P., Obach V., et al. The Early Systemic Prophylaxis of Infection After Stroke study: a randomized clinical trial. Stroke 2005; 36: 1495-1500.
23. Westendorp W.F., Nederkoorn P.J., Vermeij J.D., et al. Poststroke infection: a systematic review and meta-analysis. BMC Neurology 2011; 11: 110.
24. Fuentes B., Fernandez-Dominguez J., Ortega-Casarrubios M.A., et al. Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction. J Hypertens 2010; 28: 575-581.
25. Chitravas N., Dewey H.M., Nicol M.B., et al. Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome? Neurology 2007; 68: 1687-1693.
26. Grabska K., Gromadzka G., Czlonkowska A. Prestroke antihypertensive therapy: effect on the outcome. Clin Exp Hypertens 2013; 35: 141-147.
27. Lakhan S.E., Bagchi S., Hofer M. Statins and clinical outcome of acute ischaemic stroke: a systematic review. Int Arch Med 2010; 3: 22.
28. Cordenier A., De Smedt A., Brouns R, et al. Pre-stroke use of statins on stroke outcome: a meta-analysis of observational studies. Acta Neurol Belg 2011; 111: 261-267.
29. Squizzato A., Romualdi E., Dentali F., et al. Statins for acute ischaemic stroke. Cochrane Database Syst Rev 2011: CD007551.